Probatebeta
Target

FLT4

Vascular endothelial growth factor receptor 3

As of the edition of 20 October 2026, FLT4 (vascular endothelial growth factor receptor 3, UniProt P35916) has 43 drugs tested at it and 54 companies on the list, 18 on route A and 6 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P35916
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
4
Disease areas
Cancer; Digestive system; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Skin and connective tissue; Hormones; Blood and lymph
Registered trials of its drugs
3,588

Drugs at this target

StatusCount
Marketed10
Active7
Went quiet11
Stopped12
Status not established3
Total43
DrugStatusFurthest phaseUS protection
SorafenibMarketedPhase 4Ends 2027
LenvatinibMarketedPhase 4Ends 2035
CatequentinibActivePhase 4none listed
SunitinibMarketedPhase 4none listed
RegorafenibMarketedPhase 4Ends 2032
PazopanibMarketedPhase 4none listed
AxitinibMarketedPhase 3Ends 2030
NintedanibMarketedPhase 4Ends 2027
FruquintinibMarketedPhase 4Ends 2035
VandetanibMarketedPhase 3none listed
CediranibStoppedPhase 3none listed
SurufatinibActivePhase 4none listed

12 of 43 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A18
Route B6
Engaged22
Undetermined8
Total on the list54
Three companies on route A or B, with the route only
CompanyRoute
Jiangsu HengRui MedicineRoute A
TakedaRoute B
Bristol Myers SquibbRoute A

The other 51 companies at FLT4

In the product

54 companies in all; 51 are not named here, and no score is.

See the 54 companies at FLT4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at FLT4

Other targets in cancer

Companies holding approvals at FLT4